Basecamp Research has launched the Trillion Gene Atlas, an ambitious initiative aimed at gathering genetic information from over 100 million species worldwide. This project seeks to expand the known evolutionary genetic diversity by 100-fold, challenging the limitations of current AI models in drug discovery. CEO Glen Gowers argues that existing biological AI relies on a narrow segment of life forms, which constrains its ability to learn and innovate in therapeutic development.

The implications for longevity research are significant. Aging is a multifaceted issue characterized by various processes such as chronic inflammation and cellular damage. By broadening the biological dataset, Basecamp hopes to enhance AI’s capacity to design therapeutics that address these complex, age-related conditions. Their EDEN foundation models, trained on a vastly larger dataset, have already shown promising results, including the ability to propose diverse therapeutics from disease prompts.

Ultimately, the Trillion Gene Atlas could reshape the landscape of AI-driven drug discovery in longevity. By addressing the data limitations that have hampered progress, Basecamp aims to provide a more comprehensive biological context, potentially leading to more effective interventions for age-related diseases. This initiative underscores the need for a deeper understanding of biology to unlock the therapeutic potential of AI in the longevity sector.

Source: longevity.technology